Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors

Mayur Garg; Simon G Royce; John S Lubel

doi:10.1111/apt.15814

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors

Aliment Pharmacol Ther. 2020 Aug;52(3):569-570. doi: 10.1111/apt.15814. Epub 2020 Jun 3.

Authors

Mayur Garg^{1

2

3}, Simon G Royce⁴, John S Lubel⁵

Affiliations

¹ Department of Gastroenterology, Northern Hospital, Melbourne, Vic., Australia.
² Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Vic., Australia.
³ Department of Medicine, University of Melbourne, Melbourne, Vic., Australia.
⁴ Department of Pharmacology, Monash University, Melbourne, Vic., Australia.
⁵ Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Vic., Australia.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15893.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Coronavirus*
Humans
Inflammation
Inflammatory Bowel Diseases*
Pandemics*
Peptidyl-Dipeptidase A
Pneumonia, Viral*
SARS-CoV-2

Substances

Peptidyl-Dipeptidase A

Grants and funding

IBD-0360/Broad Medical Research Program/International